The HPV-activating Cellular Transcription Factor Brn-3a is Overexpressed in CIN3 Cervical Lesions

Daniel Ndisdang,* Peter J. Morris,* Caroline Chapman,* Linda Ho,* Albert Singer,‡ and David S. Latchman*

*Windeyer Institute of Medical Sciences, University College London Medical School, The Windeyer Building, Cleveland Street, London W1P 6DB, United Kingdom; and ‡Department of Women’s and Children’s Health, The Whittington Hospital, Highgate Hill, London N19 5NF, United Kingdom

Abstract

The cervical cellular transcription factors Brn-3a and Brn-3b have antagonistic effects on transcription of the human papilloma virus types 16 and 18 E6 and E7 oncoproteins, with Brn-3a activating expression and Brn-3b repressing it. We therefore measured expression of Brn-3a and Brn-3b mRNAs in biopsies from 16 women with no detectable cervical abnormality, and in 14 women with cervical intraepithelial neoplasia grade 3 (CIN3) lesions. Although the mean level of Brn-3b expression was similar in both groups, the mean level of Brn-3a expression was over 300-fold higher in the CIN3 samples when compared with normals. Elevated expression of Brn-3a was also detected in 16 histologically normal regions of the cervix adjacent to the CIN3 lesions, indicating that elevation of Brn-3a levels is not confined to the lesion in women with CIN3, and is thus not a consequence of the oncogenic process. The elevated levels of Brn-3a in the CIN3 patient samples, together with the activating effect of Brn-3a on HPV-16 and -18 oncogene expression, suggest that induction of this factor is involved in activating HPV-16 and -18 oncogene expression in the cervix, and hence in the production of cervical cancers induced by HPV. (J. Clin. Invest. 1998, 101:1687–1692.) Key words: cervical cancer • human papillomavirus • transcriptional regulation • Brn-3a and Brn-3b transcription factors

Introduction

The human papillomavirus types 16 and 18 (HPV-16 and HPV-18) are found in the great majority of women with cervical cancer (1, 2), and it is now generally accepted that these oncogenic viruses play a critical role in the etiology of the disease. However, both HPV-16 and HPV-18 can be detected in women with undetectable or minimal cervical abnormality (3, 4), and it is unclear what factors trigger HPV-16 or HPV-18 to initiate cellular transformation to a malignant phenotype.

The ability of HPV-16 and HPV-18 to initiate cell transformation is dependent on the virally encoded E6 and E7 oncoproteins, each of which have a role in cell transformation in culture. In turn, transcription of the genes encoding E6 and E7 is controlled by an upstream regulatory region (URR) of the virus genome that is preferentially active in cells of cervical origin (5, 6). Although numerous studies have documented binding of several cellular transcription factors to the URR (7–10), these factors are generally ubiquitously expressed and may not fully explain cervical cell–specific activity of the URR or its activation leading to disease progression in vivo.

We previously reported, however, that a cervical cell–specific regulatory activity was able to bind to a sequence (ATGCAATT) in the URR of HPV-16 and HPV-18, and to activate their expression specifically in cell lines of cervical origin (11, 12). This sequence was absent in the URR of closely related HPV-17, and only with benign warts. We subsequently showed that this activity is mediated by two distinct transcription factors (Brn-3a and Brn-3b) that are expressed in cervical cells and neuronal cells, but not in other cell types (12). Brn-3a (also known as Brn-3.0) and Brn-3b (also known as Brn-3.2) are members of the POU family of transcription factors (for review see references 16 and 17) that are closely related to one another, but are encoded by different genes. Most interestingly, while Brn-3a activates transcription via the ATGCAATT motif of the HPV URR, Brn-3b represses such transcription and interferes with activation by Brn-3a.

Brn-3a and Brn-3b thus constitute a pair of closely related transcription factors that are specifically expressed in cervical cells, and which have antagonistic effects on the activity of the URR. It is possible, therefore, that the balance between Brn-3a and Brn-3b in vivo may play a role in regulating the activity of the URR, and hence in controlling production of the oncogenic E6 and E7 proteins and in transforming cells to a malignant phenotype. We have therefore compared the expression of Brn-3a and Brn-3b in cervical material from women with no histologically detectable cervical abnormality, and in those with cervical intraepithelial neoplasia grade 3 (CIN3) lesions.

Methods

Cervical biopsies, plasmids, and HPV-16 DNA. Human cervical biopsies were obtained from women attending the Colposcopy Clinic (Whittington Hospital, Highgate Hill, United Kingdom) who were referred with abnormal cervical smears ranging from mild to severe dyskariosis. All women provided informed consent at the time of colposcopy. Ethical permission was obtained from the Whittington Hospital Ethical Committee after review of the study protocol. Samples to be tested were chosen to represent a range of histologic grades independent of HPV status. Biopsy was either by punch or loop exci-
sion. Each specimen was divided into 1-mm segments. Alternate sections of the biopsies were either transported in liquid nitrogen and stored at −70°C before nucleic acid extraction, or were sent for histology. Sections were histologically classified according to the presence of cervical intraepithelial neoplasia. High-grade lesions were those with a diagnosis of CIN2/3, and low-grade lesions were those with a diagnosis of CIN1. Normal tissues were also classified.

The biopsies were made up of (a) 14 CIN3 lesions (CIN3); (b) 16 normal samples from regions adjacent to CIN3 lesions (N-CIN); and (c) 16 normal samples from individuals with no histologically detectable cervical abnormality. Complementary DNA (cDNA) obtained from human neuroblastoma cell lines expressing Brn-3a and Brn-3b was used as a positive control for reverse transcription (RT)-PCR experiments. Water only or human fibroblast mRNA (which does not express Brn-3a or Brn-3b) was used as a negative control. Plasmids with human Brn-3a and Brn-3b cDNA were used as positive controls for PCR experiments. HPV-16 DNA was used as a positive control for subsequent HPV PCR procedures, with water, DNA, or RNA from an HPV-negative neuroblastoma cell line being used as a negative control.

**RNA and DNA extractions from human cervical biopsies and RT-PCR.** RNA was prepared using the guanidinium isothiocyanate method (20). Samples of ~33 mg were homogenized in 250 μl of a solution containing 4 M guanidinium thiocyanate, 25 mM sodium citrate, pH 7.0, 0.1 M 2-mercaptoethanol, and 0.5% N-laurolsarcosine. DNA was extracted using guanidinium isothiocyanate as previously described (21). Resultant RNA and DNA were treated with 250 μg/ml DNase and RNase, respectively. About 0.1 μg of the resultant RNA from each sample was used as a template for cDNA synthesis. The synthesized cDNA was used in RT-PCR assays as previously described (22, 23) using the following oligonucleotide primers: Brn-3a: 5’-GTCGACATGGACTGGCAGC-3’; Brn-3b: 5’-GGAGAAGAAGCTCAAGC-3’, 3’-CTGAGAACCAGAGGCT-5’. Amplification of the invariably expressed human cyclophilin mRNA used as a control was carried out in parallel using the following primers: 5’-TTGGGC-CGGGTTACTCTTTCA-3’, and 3’-TTCTGTATGCCCAGGA-CGTG-5’ (22). HPV-16 DNA and cDNA prepared from HPV-16 DNA were amplified using a hot-start of 95°C and an annealing temperature of 54°C for 35 cycles with the following primers: 5’-gagaagct-tCTGCAATGTTTCAGGACCC-3’, 3’-gagecaTGCCCAATGAA-CAGGTCTC-5’ (21).

In all cases, 20 μl of each PCR product was fractionated on a 2% agarose gel and blotted onto Hybond-N+ nylon membrane (Amer sham International, Little Chalfont, United Kingdom) and hybridized with homologous complimentary 32P-labeled probes. Membranes were exposed to films, (Eastman Kodak Co., Rochester, NY) and the subsequent autoradiographs were then analyzed using a densitometer (Bio-Rad Laboratories, Hercules, CA). We have previously shown that this blotting procedure, in conjunction with the RT-PCR conditions used, allows accurate quantification of the Brn-3a and Brn-3b mRNAs relative to the constitutively expressed cyclophilin mRNA (14, 22−25).

**Western blotting.** Samples for Western blot protein assay were made up of 11 CIN3 lesions, 10 normal samples from adjacent regions, and 13 normal samples from women with no histologically detectable abnormality. The samples were resuspended in sample buffer containing 2.3% sodium dodecyl sulphate, 0.0625 M Tris/HCl, pH 7.9, 10% glycerol, 5% 2-mercaptoethanol, and bromphenol blue. Samples were sonicated for 10 s, and then boiled for 2 min. The samples had equal protein content as determined by the method of Bradford (26), and were split in two and run on two sides of the same SDS-polyacrylamide gel. After electrophoresis, one half of the gel was stained with Coomassie blue and then destained, while the other half was transferred to nitrocellulose and probed with antibody to Brn-3a or Brn-3b (Bab Co Ltd) as previously described (27). Levels of Brn-3a or Brn-3b in each sample were quantified by densitometric scanning of the resulting autoradiograph. Differences in the level of total protein in each sample were determined by scanning the actin band on the stained portion of the gel to normalize the samples (27).

**Results**

To measure the Brn-3a and Brn-3b mRNAs in the limited amounts of material available from human cervical biopsies, we used an RT-PCR assay that we had previously used to measure the levels of Brn-3a/Brn-3b and other POU family transcription factors in limited amounts of material (24, 25). The levels of amplification product obtained after amplification of the Brn-3a and Brn-3b mRNAs with specific primers was compared to that of the constitutively expressed cyclophilin mRNA in each sample to control for any differences in the amount of total RNA or amplification efficiency in each sample (Fig. 1).

After densitometric scanning of results of this kind, the level of the Brn-3a and Brn-3b mRNAs was quantitated in 16 cervical samples derived from individuals with no histologically detectable cervical abnormality, and 14 CIN3 (CINIII) samples. The levels of mRNA observed in replicate determinations using the same sample varied by <10%, confirming the reliability of the assay (data not shown). The results of the analysis (Fig. 2 and Table I) revealed virtually no change in expression of Brn-3a mRNA between the normal and CIN3 samples with a similar mean level and an overlapping range of values between the two samples. In contrast, the mean level of the Brn-3a mRNA was elevated approximately 300-fold in the CIN3 samples when compared with the normals (Fig. 3 and 4).

*Figure 1.* Results of RT-PCR amplification of the Brn-3a (A), Brn-3b (B), or control cyclophilin (C) mRNAs in three samples obtained from women with no histologically detectable cervical abnormality (N), or three samples from CIN3 lesions (3). The positive control of cDNA prepared from human neuroblastoma mRNA (+) and the negative control of no cDNA (−) are also indicated.
Indeed, the CIN3 samples with the lowest level of Brn-3a mRNA still had approximately 6-fold more mRNA than did the highest normal samples. The levels of Brn-3a mRNA were at the limit of detection in five of the normal samples, and were undetectable in the remainder.

These dramatic changes in the level of Brn-3a mRNA in the CIN3 samples compared with similar levels of Brn-3b resulted in a very large elevation in the Brn-3a:Brn-3b ratio in the CIN3 when compared with normal samples (Table I). As the ratio between the Brn-3a activator and the Brn-3b repressor critically determines the activity of the HPV URR (19), it is likely that this effect plays a key role in activation of HPV gene expression in the CIN3 patients.

Evidently, this elevation of Brn-3a could either be confined to the CIN3 region of these patients, or could represent a more widespread elevation in the patients with CIN3 that also occurred in adjacent histologically normal regions of the cervix. To distinguish these possibilities, we determined the levels of Brn-3a and Brn-3b in further material from CIN3 patients that was derived from adjacent regions of the cervix with no detect-

![Figure 2](image1.png)

**Table I. Levels of Brn-3a and Brn-3b in Individuals With No Detectable Cervical Abnormality, CIN3 Lesions, and Regions Adjacent to a CIN3 Lesion (N-CIN)**

<table>
<thead>
<tr>
<th></th>
<th>Normal</th>
<th>CIN3</th>
<th>N-CIN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brn-3a</td>
<td>0.001±0.003</td>
<td>0.46±0.30</td>
<td>0.42±0.31</td>
</tr>
<tr>
<td>Brn-3b</td>
<td>0.11±0.11</td>
<td>0.11±0.18</td>
<td>0.07±0.09</td>
</tr>
<tr>
<td>Brn-3a/Brn-3b</td>
<td>0.01</td>
<td>4.2</td>
<td>6.0</td>
</tr>
<tr>
<td>Sample size</td>
<td>16</td>
<td>14</td>
<td>16</td>
</tr>
</tbody>
</table>

![Figure 3](image2.png)

**Figure 2.** Brn-3b mRNA levels in cervical samples from women with no histologically detectable abnormality (N), from CIN3 regions (CIN3), or from normal samples adjacent to a CIN3 lesion (N-CIN). The horizontal bar shows the mean in each group, and the number of samples in each group is indicated (n).

**Table II. Levels of Brn-3a mRNA HPV DNA and HPV RNA in a Single Individual With CIN3**

<table>
<thead>
<tr>
<th>Section DNA level</th>
<th>Brn-3a mRNA level</th>
<th>HPV E6/E7 RNA level</th>
<th>HPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.075</td>
<td>Undetectable</td>
<td>0.87</td>
</tr>
<tr>
<td>2</td>
<td>0.72</td>
<td>0.31</td>
<td>0.80</td>
</tr>
<tr>
<td>3</td>
<td>0.30</td>
<td>0.04</td>
<td>0.90</td>
</tr>
<tr>
<td>4</td>
<td>0.63</td>
<td>0.30</td>
<td>0.80</td>
</tr>
</tbody>
</table>

Values are in arbitrary densitometric units equalized for the level of cyclophilin mRNA in each sample.
able abnormality, and that had no detectable expression of HPV E6 and E7 mRNA or HPV 16 DNA (data not shown). In these experiments, the samples exhibited a mean level of Brn-3a mRNA that was only marginally lower than that of the CIN3 region, and was dramatically more than what was detectable in the normal samples obtained from individuals with no histologically detectable abnormality anywhere in the cervix (Fig. 3 and Table I).

Together with a similar level of Brn-3b expression in these samples (Fig. 2), this resulted in a Brn-3a:Brn-3b ratio that was similar to that in the CIN3 samples, and was much greater than that of normal individuals (Table I). Hence, the elevated levels of Brn-3a and of the Brn-3a:Brn-3b ratio appear to be characteristic of both the CIN3 area and the adjacent area of the cervix of individuals with CIN3 compared with normal cervical tissue rather than of the actual area of malignancy alone.

To further extend these results to the protein level, we carried out Western blotting experiments using extracts from the various samples and antibodies to Brn-3a and Brn-3b. These results (Figs. 4 and 5) paralleled the results obtained at the mRNA level. Thus, the mean level of Brn-3b was similar in all the groups (Fig. 4), while the level of Brn-3a was greatly elevated in CIN3 samples and normal samples from adjacent regions compared with the results obtained with normal samples from women with no detectable cervical abnormality (Fig. 5).

Although virtually all the samples from CIN3 patients had a uniformly high level of Brn-3a, we did identify a patient in whom four adjacent CIN3 sections had different levels of Brn-3a, including one having the lowest level detected in a CIN3 sample (Table II). This sample provided us with a unique opportunity to test the hypothesis that Brn-3a levels regulate transcription of the HPV genome. To do this, the level of HPV DNA and of HPV E6 and E7 RNA transcripts was measured using PCR amplification. In this experiment (Table II) all four regions had a similar level of HPV DNA, but the level of HPV E6 and E7 RNA transcripts detected was different in each case when compared with the level of the invariant cyclophilin mRNA. No signal was obtained with the HPV primers and DNA or mRNA prepared from an HPV-negative human neuroblastoma cell line, confirming the specificity of the assay. Most interestingly, HPV E6 and E7 RNA was undetectable in the sample with minimal Brn-3a levels, was present at low levels in the sample with intermediate Brn-3a levels, and was found at high levels in the two samples with high Brn-3a levels.
cells. Alternatively, it is possible that the elevated Brn-3a levels in individuals with CIN3 reflect variation in the human population produced during cervical development and differentiation that affects HPV transcription. Whatever the case, it is clear that a dramatic elevation in Brn-3a levels is characteristic of women with high-grade cervical lesions compared with individuals with no detectable cervical abnormality.

Acknowledgments

This work was supported by Wellbeing (The Health Research Charity for Women and Babies).

References

Brn-3 family of POU transcription factors: a new amino terminal domain is crucial for the oncogenic activity of Brn-3A. *Nucleic Acids Res.* 21:5921–5929.


